In addition, we observed nominal increased expression between participants with neuropathologically confirmed AD compared with controls in FLT1 and FLT4 (corrected p > 0.05, p < 0.01; Supplementary Figs. 1A and 2A), which replicated among Mayo participants in the temporal cortex for FLT4 (corrected p = 0.006) and in both the cerebellum and temporal cortex for FLT1 (corrected p < 0.02). This evidence concerns the gene FLT4 and Alzheimer disease.